Tencent led a series A2 round for the cell analysis technology developer that included Lilly Asia Ventures and Softbank China Venture Capital.
China-based molecular diagnostics technology provider Singleron Biotechnologies has raised $30m in a series A2 round led by internet group Tencent, DealStreetAsia has reported.
The round included Softbank China Venture Capital, which invests on behalf of telecommunications and internet group SoftBank; Lilly Asia Ventures, an investment vehicle for pharmaceutical firm Eli Lilly; CDH Investments and Sherpa Healthcare Partners.
Founded in 2018, Singleron has developed single cell analysis technology for use in clinical diagnosis, drug development and healthcare management. It will use…
